2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006010027v1 17/11/3240    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imoagene-Oyedeji, A. E. Articles by Bloom, R. D. Search for Related Content PubMed PubMed Citation Articles by Imoagene-Oyedeji, A. E. Articles by Bloom, R. D. Related Collections Related Articles

Posttransplantation Anemia at 12 Months in Kidney Recipients Treated with Mycophenolate Mofetil: Risk Factors and Implications for Mortality

Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Address correspondence to: Dr. Roy D. Bloom, Renal-Electrolyte and Hypertension Division, University of Pennsylvania, 700 Clinical Research Building, 415 Curie Boulevard, Philadelphia, PA 19104-6144. Phone: 215-662-4643; Fax: 215-615-0349; rdbloom{at}mail.med.upenn.edu

Received for publication January 11, 2006. Accepted for publication August 29, 2006.

Although posttransplantation anemia (PTA) is common in the mycophenolate mofetil era, its impact on patient survival is unknown. This retrospective cohort study characterized factors that are associated with PTA 12 mo after transplantation in mycophenolate mofetil–treated kidney recipients and explored whether 12-mo PTA affects outcomes. The records of 626 kidney recipients were examined for presence of anemia (hemoglobin <12 g/dl). Multivariate regression models, fit with covariates that had unadjusted relationships, investigated both risk factors for 12-mo PTA and whether 12-mo PTA contributes to mortality. Anemia prevalence was 72, 40, and 20.3% at 1, 3, and 12 mo, respectively. By multivariate logistic regression, anemia at 3 mo (odds ratio [OR] 10.0; 95% confidence interval [CI] 5.3 to 17.1; P = 0.0001), donor age (OR 1.0; 95% CI 1.1 to 1.3; P = 0.005), and 3-mo creatinine (OR 2.0; 95% CI 1.2 to 3.3; P = 0.044) were associated with 12-mo PTA. The PTA cohort had inferior patient survival (P = 0.02, log rank) and a higher proportion of cardiovascular deaths (6.3 versus 2.2%; P = 0.017) than nonanemic patients. By Cox regression, 12-mo PTA (hazard ratio [HR] 3.0; 95% CI 1.3 to 6.7; P = 0.009), 12-mo creatinine (HR 1.3; 95% CI 1.1 to 1.4; P = 0.008), age at transplantation (HR 1.1; 95% CI 1.1 to 1.2; P = 0.004), and hepatitis C seropositivity (HR 2.8; 95% CI 1.1 to 7.0; P = 0.03) were associated with mortality. There was no interaction between 12-mo PTA and serum creatinine. In conclusion, 12-mo PTA is associated with an increased risk for patient death. The presence of anemia 3 mo after kidney transplantation is a major determinant of 12-mo PTA. PTA in kidney recipients therefore should be defined by its persistence or occurrence beyond the third posttransplantation month.

Related Articles

This Month’s Highlights
J. Am. Soc. Nephrol. 2006 17: 2947-2948. [Full Text] [PDF]

This article has been cited by other articles:

				D. Chhabra, M. Grafals, A. I. Skaro, M. Parker, and L. Gallon Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1168 - 1174. [Abstract] [Full Text] [PDF]

				R. Borrows, M. Loucaidou, G. Chusney, S. Borrows, J. V. Tromp, T. Cairns, M. Griffith, N. Hakim, A. McLean, A. Palmer, et al. Anaemia and congestive heart failure early post-renal transplantation Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1728 - 1734. [Abstract] [Full Text] [PDF]

				J. S. Gill Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S29 - S37. [Abstract] [Full Text] [PDF]

				W. C. Winkelmayer and A. Chandraker Pottransplantation Anemia: Management and Rationale Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S49 - S55. [Abstract] [Full Text] [PDF]

				J. J. Augustine and D. E. Hricik Anemia after Kidney Transplantation: Time for Action J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2962 - 2963. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673